Dune Therapeutics runs large-scale genomic screening and in silico validation workflows to identify novel protein targets in rare monogenic diseases. The team, based in Perth and partnered with UWA's genetics group, combines patient cohort data with AlphaFold predictions to de-risk early-stage R&D. Current pipeline includes three undisclosed rare disease indications.